Pacer Advisors’s Myriad Genetics MYGN Stock Holding History

Pacer Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-532	Closed	-$13K	–	2642
2024 Q2	$13K	Sell	532 -628	-54%	-$13.8K	﹤0.01%	3510
2024 Q1	$24.7K	Buy	+1,160	New	+$24.9K	﹤0.01%	3402
2021 Q2	–	Sell	-2,510	Closed	-$76K	–	1496
2021 Q1	$76K	Sell	2,510 -396	-14%	-$11.2K	﹤0.01%	1338
2020 Q4	$57K	Sell	2,906 -2,936	-50%	-$47.4K	﹤0.01%	1405
2020 Q3	$76K	Buy	+5,842	New	+$73.9K	﹤0.01%	1283
2018 Q4	–	Sell	-5,140	Closed	-$236K	–	864
2018 Q3	$236K	Buy	+5,140	New	+$229K	0.01%	997
2018 Q2	–	Sell	-1,588	Closed	-$47K	–	1185
2018 Q1	$47K	Sell	1,588 -462	-23%	-$15.6K	﹤0.01%	970
2017 Q4	$70K	Buy	+2,050	New	+$69.2K	﹤0.01%	987
2017 Q3	–	Sell	-1,390	Closed	-$36K	–	1234
2017 Q2	$36K	Buy	+1,390	New	+$29.5K	﹤0.01%	1136

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Pacer Advisors's MYGN Position: Q3 2024 in Review

Pacer Advisors sold out of Myriad Genetics (MYGN) in Q3 2024, closing a stake of 532 shares — an estimated $13K sold.

Pacer Advisors first reported a position in MYGN in Q2 2017 and held it in 9 quarters. The position peaked at $236K in Q3 2018. 246 funds tracked by Wall St. Rank hold MYGN as of Q3 2024.

Pacer Advisors reported no remaining Myriad Genetics position as of Q3 2024 after selling out during the quarter.
Pacer Advisors sold 532 Myriad Genetics shares in Q3 2024, an estimated $13K.
Pacer Advisors first reported a position in Myriad Genetics in Q2 2017 and held it in 9 quarters.
Pacer Advisors's Myriad Genetics position peaked at $236K in Q3 2018.
246 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.